BIO

NYSE Healthcare

Bio-Rad Laboratories, Inc. Class A Common Stock

Medical Devices

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

๐Ÿ“Š Market Data
Price$256.55
Volume939,938
Market Cap6.93B
RSI (14-Day)34.1
200-Day MA$292.34
50-Day MA$277.31
52-Week High$343.12
52-Week Low$211.43
P/E Ratio42.76
Forward P/E22.61
Price / Book1.00
๐ŸŽฏ Investment Strategy Scores

BIO scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 30/100โ–ฒ +8
High dividend yield + low volatility
๐Ÿš€ Moon Shot 25/100โ–ผ -46
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 88/100โ–ฒ +19
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 8/100โ–ผ -23
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (88/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (8/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find BIO in your text

Paste any article, transcript, or post โ€” the tool will extract BIO and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.